I-Mab (IMAB) |
|
12.35 0.36 (3%)
|
06-26 19:47 |
|
Open: |
12.31 |
Pre. Close: |
11.99 |
|
High:
|
12.53 |
Low:
|
11.71 |
|
Volume:
|
593,332 |
Market Cap:
|
1,021(M) |
|
|
|
|
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.55 - 12.6 |
12.6 - 12.65 |
|
Low:
|
11.59 - 11.64 |
11.64 - 11.69 |
|
Close:
|
12.26 - 12.35 |
12.35 - 12.43 |
|
Technical analysis |
as of: 2022-06-24 4:40:50 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 14.63  One year: 17.09 |
| Support: |
Support1: 9.76 Support2: 8.05 |
| Resistance: |
Resistance1: 12.52 Resistance2: 14.63 |
| Pivot: |
10.38 |
| Moving Average: |
MA(5): 11.74 MA(20): 9.91
MA(100): 15.78 MA(250): 43.02 |
| MACD: |
MACD(12,26): 0.1 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 93.2 %D(3): 92.9 |
| RSI: |
RSI(14): 60 |
| 52-week: |
High: 84.05 Low: 8.05 |
| Average Vol(K): |
3-Month: 1,420 (K) 10-Days: 931 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IMAB ] has closed below upper band by 9.3%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 23 Jun 2022
I-Mab Valuation Offers A Biotech Investment Opportunity (NASDAQ:IMAB) - Seeking Alpha
Thu, 23 Jun 2022
2022-06-23 | NDAQ:IMAB | Press Release | I-MAB - Stockhouse
Tue, 21 Jun 2022
Is it Time to Dump I-Mab ADR (IMAB) Stock After it Is Up 32.36% in a Week? - InvestorsObserver
Thu, 16 Jun 2022
I-Mab (NASDAQ:IMAB) Shares Up 4.4% - Defense World
Wed, 15 Jun 2022
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 - BioSpace
Thu, 09 Jun 2022
I-Mab, Ferring team up to develop olamkicept for inflammatory bowel disease - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
78 (M) |
|
% Held by Insiders
|
3.792e+007 (%) |
|
% Held by Institutions
|
1 (%) |
|
Shares Short
|
3,860 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.99e+009 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
274 |
|
Return on Equity (ttm)
|
-21 |
|
Qtrly Rev. Growth
|
8.803e+007 |
|
Gross Profit (p.s.)
|
-119.15 |
|
Sales Per Share
|
-55.68 |
|
EBITDA (p.s.)
|
5.07195e+007 |
|
Qtrly Earnings Growth
|
-0.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.23 |
|
Price to Cash Flow
|
0.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
4.06e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
